Caliway Announces Positive Phase 2 Results of CBL-514 in Dercum's Disease, Achieving Primary Endpoint with Statistically Significant and Sustained Pain Reduction
Primary Endpoint Achieved in CBL-0202DD Phase 2 Trial—CBL-514 delivered statistically significant pain reduction across both FAS and PP populations compared with placebo. Expansion Opportunity Beyond Dercum's Disease—Study findings support the...
Merry Life Biomedical Advances Global Phase 2 Trial of TML-6, Exploring Cellular Protein Clearance in Early Alzheimer's Disease
Global study brings together nine Taiwan medical centers, seven Swedish sites, and four U.S. centers to evaluate an oral therapy focused on autolysosomal biology TAIPEI, Sept. 22, 2026 /PRNewswire/ -- Merry Life Biomedical today announced the...
Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease
CAMBRIDGE, Mass. and TAIPEI, June 11, 2026 /PRNewswire/ -- Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmune diseases, today announced...
From SCAN to SPARK: Galaxy Brain Scientific Enables a New Paradigm in Non-invasive, Personalized Precision Treatment for Parkinson's Disease
BEIJING, March 25, 2026 /PRNewswire/ -- A research team led by Prof. Hesheng Liu, founder and Chief Scientific Officer of Galaxy Brain Scientific Inc., has published a study in Nature Neuroscience demonstrating that Deep Brain Stimulation (DBS)...
Global Appeal 2026: Education as the Key to Ending Leprosy Stigma and Discrimination
— Launch Event in Brussels Will Be Live-Streamed Worldwide — TOKYO, Jan. 28, 2026 /PRNewswire/ -- The transformative power of education in replacing fear with knowledge and prejudice with empathy lies at the heart of the Global Appeal 2026 to End...
Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale from baseline of +0.64 points, compared to natural history expected worsening of cUHDRS in symptomatic patients of -0.73 points over nine months, based...
Alzheimer's Association Statement on Oral Semaglutide Phase 3 Topline Data Release
- Results Underscore Need for Continued Research and Diverse Treatment Pipeline CHICAGO, Nov. 24, 2025 /PRNewswire/ -- The Alzheimer's Association is disappointed that the evoke and evoke+ clinical trials did not demonstrate a statistically...
FDA Grants Fast Track Designation for AJ201, a First-in-Class Therapy for Kenndy's Disease
TAIPEI, Oct. 23, 2025 /PRNewswire/ -- AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track Designation for AJ201, the first-in-class for therapy for spinal and...
Skyhawk Therapeutics Announces First Patient Dosed in Phase 2/3 FALCON-HD Trial of SKY-0515 for Huntington's Disease
SKY-0515 is an oral small molecule designed to reduce the production of both huntingtin (HTT) and PMS1 proteins—two key drivers of HD pathology Initiation of the FALCON-HD trial follows promising Phase 1 results demonstrating up to 72% reduction in...
NUZ-001 Shows Promise in Zebrafish Model of Huntington's Disease
Highlights: NUZ-001 and its active metabolite NUZ-001 Sulfone demonstrated significant neuroprotective effects in a zebrafish model of Huntington's disease Treatment prevented hallmark developmental and morphological abnormalities, protected against...